Charles River Laboratories International, Inc. (CRL)
Automate Your Wheel Strategy on CRL
With Tiblio's Option Bot, you can configure your own wheel strategy including CRL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CRL
- Rev/Share 81.9674
- Book/Share 69.169
- PB 2.2632
- Debt/Equity 0.8308
- CurrentRatio 1.3604
- ROIC 0.0687
- MktCap 7599164622.0
- FreeCF/Share 11.7702
- PFCF 13.1361
- PE -109.6294
- Debt/Assets 0.3685
- DivYield 0
- ROE -0.0201
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | CRL | Jefferies | Hold | Buy | -- | $195 | Sept. 9, 2025 |
| Upgrade | CRL | Citigroup | Neutral | Buy | -- | $200 | July 9, 2025 |
| Upgrade | CRL | Redburn Atlantic | Neutral | Buy | -- | $182 | May 23, 2025 |
| Upgrade | CRL | TD Cowen | Hold | Buy | -- | $179 | May 14, 2025 |
| Upgrade | CRL | Evercore ISI | In-line | Outperform | -- | $170 | May 8, 2025 |
| Downgrade | CRL | Goldman | Buy | Neutral | $190 | $170 | March 21, 2025 |
| Upgrade | CRL | Citigroup | Sell | Neutral | $155 | $175 | March 4, 2025 |
| Upgrade | CRL | Redburn Atlantic | Sell | Neutral | -- | $188 | March 3, 2025 |
| Downgrade | CRL | William Blair | Outperform | Market Perform | -- | -- | Jan. 22, 2025 |
| Downgrade | CRL | UBS | Buy | Neutral | $250 | $185 | Jan. 17, 2025 |
News
What's Going On With Charles River, Certara, Simulations Plus Stocks On Friday?
Published: April 11, 2025 by: Benzinga
Sentiment: Neutral
The U.S. Food and Drug Administration announced a major shift in how monoclonal antibody therapies and other drugs are evaluated, emphasizing a transition from traditional animal testing.
Read More
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Published: April 10, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Read More
Charles River (CRL) Up 1.9% Since Last Earnings Report: Can It Continue?
Published: March 21, 2025 by: Zacks Investment Research
Sentiment: Positive
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Read More
Charles River Laboratories International, Inc. (CRL) Q4 2024 Earnings Call Transcript
Published: February 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Charles River Laboratories International, Inc. (NYSE:CRL ) Q4 2024 Earnings Call February 19, 2025 8:30 AM ET Company Participants Todd Spencer - Vice President, Investor Relations Jim Foster - Chair, President and Chief Executive Officer Flavia Pease - Executive Vice President and Chief Financial Officer Conference Call Participants Elizabeth Anderson - Evercore Matt Sykes - Goldman Sachs Tejas Savant - Morgan Stanley Dave Windley - Jefferies Ann Hynes - Mizuho Justin Bowers - Deutsche Bank Lucas Romanski - TD Cowen Michael Ryskin - Bank of America Max Smock - William Blair Jacob Johnson - Stephens Patrick Donnelly - Citi Casey …
Read More
CRL Stock Up on Q4 Earnings and Revenue Beat, Margins Fall
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Neutral
Charles River's organic revenue growth in Manufacturing Solutions is more than offset by lower revenues in the RMS and DSA segments.
Read More
Compared to Estimates, Charles River (CRL) Q4 Earnings: A Look at Key Metrics
Published: February 19, 2025 by: Zacks Investment Research
Sentiment: Positive
The headline numbers for Charles River (CRL) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Read More
Is Now the Right Time to Hold on to Charles River Stock?
Published: February 14, 2025 by: Zacks Investment Research
Sentiment: Positive
CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.
Read More
About Charles River Laboratories International, Inc. (CRL)
- IPO Date 2000-06-23
- Website https://www.criver.com
- Industry Medical - Diagnostics & Research
- CEO James C. Foster
- Employees 18700